Castrate-Resistant Prostate Cancer Market Size, Trends, Report: By Therapy Type: Hormonal Therapy, Immunotherapy, Chemotherapy, Others; By Therapy Drug Class: Antineoplastic, Non-steroidal Antiandrogen, Corticosteroids, Others; By Route of Administration; Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Castrate-Resistant Prostate Cancer Overview
    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Castrate-Resistant Prostate Cancer Epidemiology Analysis-7MM
    5.1    Epidemiology Overview (2016-2031)
    5.2    United States Castrate-Resistant Prostate Cancer Epidemiology (2016-2031)
    5.3    EU-4 and United Kingdom Castrate-Resistant Prostate Cancer Epidemiology (2016-2031)
    5.4    Japan Castrate-Resistant Prostate Cancer Epidemiology (2016-2031)
6     Castrate-Resistant Prostate Cancer Market Overview 
    6.1     Castrate-Resistant Prostate Cancer Market Historical Value (2017-2023) 
    6.2     Castrate-Resistant Prostate Cancer Market Forecast Value (2024-2032) 
7     Castrate-Resistant Prostate Cancer Market Landscape
    7.1    Castrate-Resistant Prostate Cancer: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Castrate-Resistant Prostate Cancer: Product Landscape
        7.2.1    Analysis by Therapy Type
        7.2.2    Analysis by Drug Class
        7.2.3    Analysis by Route of Administration
8    Castrate-Resistant Prostate Cancer Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10     Castrate-Resistant Prostate Cancer Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11     Castrate-Resistant Prostate Cancer Market Segmentation
    11.1     Castrate-Resistant Prostate Cancer Market by Therapy Type
        11.1.1    Market Overview
        11.1.2    Hormonal Therapy
        11.1.3    Immunotherapy
        11.1.4    Chemotherapy
        11.1.5    Others
    11.2     Castrate-Resistant Prostate Cancer Market by Therapy Drug Class
        11.2.1    Market Overview
        11.2.2    Antineoplastic
        11.2.3    Non-steroidal Antiandrogen
        11.2.4    Corticosteroids
        11.2.5    Others
    11.3     Castrate-Resistant Prostate Cancer Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
        11.3.3    Parenteral
    11.4     Castrate-Resistant Prostate Cancer Market by Distribution Channel
        11.4.1    Market Overview
        11.4.2    Hospital Pharmacy
        11.4.3    Retail Pharmacy
        11.4.4    Online Pharmacy
    11.5     Castrate-Resistant Prostate Cancer Market by Region -7MM
        11.5.1    Market Overview
        11.5.2    United States
        11.5.3    EU-4 and the United Kingdom
        11.5.4    Japan
12    United States Castrate-Resistant Prostate Cancer Market
    12.1    U.S. Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)  
    12.2    U.S. Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)  
    12.3    Market Size by Therapeutic Class
13    EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market
    13.1    EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)  
    13.2    EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)  
    13.3    Market Size by Therapeutic Class
14    Japan Castrate-Resistant Prostate Cancer Market
    14.1    Japan Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)  
    14.2    Japan Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)  
    14.3    Market Size by Therapeutic Class
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    JAPAN PMDA
16    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17    Grants Analysis
    17.1    Analysis by year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization 
18    Clinical Trials Analysis
    18.1     Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19    Funding and Investment Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20    Partnership and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21    Supplier Landscape
    21.1    Sanofi 
        21.1.1    Financial Analysis
        21.1.2    Product Portfolio
        21.1.3    Demographic Reach and Achievements
        21.1.4    Mergers and Acquisitions
        21.1.5    Certifications
    21.2    Johnson & Johnson Services Inc.
        21.2.1    Financial Analysis
        21.2.2    Product Portfolio
        21.2.3    Demographic Reach and Achievements
        21.2.4    Mergers and Acquisitions
        21.2.5    Certifications
    21.3    Pfizer Inc.
        21.3.1    Financial Analysis
        21.3.2    Product Portfolio
        21.3.3    Demographic Reach and Achievements
        21.3.4    Mergers and Acquisitions
        21.3.5    Certifications
    21.4    Astellas Pharma, Inc.
        21.4.1    Financial Analysis
        21.4.2    Product Portfolio
        21.4.3    Demographic Reach and Achievements
        21.4.4    Mergers and Acquisitions
        21.4.5    Certifications
    21.5    Bayer AG
        21.5.1    Financial Analysis
        21.5.2    Product Portfolio
        21.5.3    Demographic Reach and Achievements
        21.5.4    Mergers and Acquisitions
        21.5.5    Certifications
    21.6    F. Hoffmann-La Roche Ltd. 
        21.6.1    Financial Analysis
        21.6.2    Product Portfolio
        21.6.3    Demographic Reach and Achievements
        21.6.4    Mergers and Acquisitions
        21.6.5    Certifications
    21.7    Mylan N.V.  
        21.7.1    Financial Analysis
        21.7.2    Product Portfolio
        21.7.3    Demographic Reach and Achievements
        21.7.4    Mergers and Acquisitions
        21.7.5    Certifications
    21.8    Teva Pharmaceutical Industries Ltd. 
        21.8.1    Financial Analysis
        21.8.2    Product Portfolio
        21.8.3    Demographic Reach and Achievements
        21.8.4    Mergers and Acquisitions
        21.8.5    Certifications
    21.9    GlaxoSmithKline plc 
        21.9.1    Financial Analysis
        21.9.2    Product Portfolio
        21.9.3    Demographic Reach and Achievements
        21.9.4    Mergers and Acquisitions
        21.9.5    Certifications
    21.10    Novartis AG 
        21.10.1    Financial Analysis
        21.10.2    Product Portfolio
        21.10.3    Demographic Reach and Achievements
        21.10.4    Mergers and Acquisitions
        21.10.5    Certifications
    21.11    Eli Lilly and Company 
        21.11.1    Financial Analysis
        21.11.2    Product Portfolio
        21.11.3    Demographic Reach and Achievements
        21.11.4    Mergers and Acquisitions
        21.11.5    Certifications
    21.12    Merck & Co., Inc. 
        21.12.1    Financial Analysis
        21.12.2    Product Portfolio
        21.12.3    Demographic Reach and Achievements
        21.12.4    Mergers and Acquisitions
        21.12.5    Certifications
    21.13    Allergan 
        21.13.1    Financial Analysis
        21.13.2    Product Portfolio
        21.13.3    Demographic Reach and Achievements
        21.13.4    Mergers and Acquisitions
        21.13.5    Certifications
    21.14    AstraZeneca 
        21.14.1    Financial Analysis
        21.14.2    Product Portfolio
        21.14.3    Demographic Reach and Achievements
        21.14.4    Mergers and Acquisitions
        21.14.5    Certifications
    21.15    Cipla Inc. 
        21.15.1    Financial Analysis
        21.15.2    Product Portfolio
        21.15.3    Demographic Reach and Achievements
        21.15.4    Mergers and Acquisitions
        21.15.5    Certifications
    21.16    Amneal Pharmaceuticals LLC
        21.16.1    Financial Analysis
        21.16.2    Product Portfolio
        21.16.3    Demographic Reach and Achievements
        21.16.4    Mergers and Acquisitions
        21.16.5    Certifications
22    Castrate-Resistant Prostate Cancer - Distribution Model (Additional Insight)
    22.1    Overview 
    22.2    Potential Distributors 
    22.3    Key Parameters for Distribution Partner Assessment 
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company Competitiveness Analysis (Additional Insight)
    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.